Table 1. Targeted agents and clinical trials for gastric and gastroesophageal cancers.
| Class | Agent | Clinical trials |
|---|---|---|
| VEGFR inhibitors | ||
| Monoclonal antibody | Bevacizumab | Phase III |
| Ramucirumab | Phase III | |
| Receptor tyrosine kinase | Sunitinib | Phase II |
| Sorafenib | Phase I/II | |
| Pazopanib | Phase II | |
| Vandetanib | Phase I/II | |
| Telatinib | Phase II | |
| EGFR inhibitors | ||
| Monoclonal antibody | Cetuximab | Phase III |
| Panitumumab | Phase III | |
| Receptor tyrosine kinase | Gefitinib | Phase III |
| Erlotinib | Phase II | |
| HER2 inhibitors | ||
| Monoclonal antibody | Trastuzumab | Phase III |
| Pertuzumab | Phase III | |
| TDM-1 | Phase II/III | |
| Receptor tyrosine kinase | Lapatinib | Phase III |
| c-Met inhibitors | ||
| Receptor tyrosine kinase | Foretinib | Phase II |
| Monoclonal antibody | Rilotumumab | Phase II/III |
| Onartuzumab | Phase II/III | |
| PARP inhibitors | ||
| Olaparib | Phase II/III | |
| Veliparib | Phase I | |
VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor type 2; PARP, poly-adenosine diphosphate ribose polymerase.